Department of Biology and Medicine, College of Food and Bioengineering, Xihua University, Chengdu 610039, China.
Department of Chemistry, College of Science, Xihua University, Chengdu 610039, China.
Med Chem. 2022;18(6):655-666. doi: 10.2174/1573406418666211130150821.
Alzheimer's disease (AD) and Parkinson's (PD) disease are common neurodegenerative conditions of the Central Nervous System (CNS). Thus, these diseases have only been treated symptomatically since no approved drug is available that provides a complete cure.
Through reading relevant literatures published at home and abroad, the method and significance of prodrug strategy to increase the efficacy of ad and pd drugs were discussed.
The biological mechanisms and currently approved drugs for both diseases have been discussed, revealing that most of these treatments utilized existing prodrug design strategies, including increased lipophilicity, and the use of transporters mediation and bio-oxidation to improve oral bioavailability and brain permeability.
The purpose of this paper is to review the research progress in the treatment of Neurodegenerative Diseases (NDDS), especially ad and pd, using the prodrug strategy. The research of drug bioavailability and the prodrug strategy of cns targeted drug delivery lay the foundation for drug development to treat these diseases.
The use of prodrug strategies provides important opportunities for the development of novel therapies for ad and pd.
阿尔茨海默病（AD）和帕金森病（PD）是常见的中枢神经系统（CNS）神经退行性疾病。因此，由于没有有效的药物能够完全治愈，这些疾病只能对症治疗。
通过阅读国内外发表的相关文献，探讨前药策略提高 AD 和 PD 药物疗效的方法和意义。
讨论了这两种疾病的生物机制和目前已批准的药物，结果表明，这些治疗方法大多利用了现有的前药设计策略，包括增加脂溶性、利用转运体介导和生物氧化来提高口服生物利用度和脑渗透性。
本文旨在综述前药策略治疗神经退行性疾病（NDDS），特别是 AD 和 PD 的研究进展。药物生物利用度的研究和中枢神经系统靶向药物递送的前药策略为开发治疗这些疾病的药物奠定了基础。
前药策略的应用为 AD 和 PD 的新型疗法的发展提供了重要机会。
